FDA approves first biosimilar for the treatment of certain breast and stomach cancers

December 1, 2017 – The U.S. Food and Drug Administration today approved trastuzumab-dkst as a biosimilar to trastuzumab for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Trastuzumab-dkst is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for … (leggi tutto)